- Vardenafil Improves Lower Urinary Tract Symptoms in Patients of Erectile Dysfunction
-
Song SH, Hong B, You D, Ahn TY
- KMID: 2299440
- Korean J Androl.
- 2006 Apr;24(1):13-17.
PURPOSE: It is well known that male erectile dysfunction and lower urinary tract symptoms are common in aging men. We evaluated whether treatment for erectile dysfunction with vardenafil might improve... -
- CITED
-
- Close
- SHARE
-
- Close
- Preliminary Study of Effects of Type V Phosphodiesterase Inhibitor(Vardenafil) on Oxytocin Expression in the Rat Paraventricular Nucleus
-
Joo KJ, Park HJ, Kim KH
- KMID: 2298610
- Korean J Androl.
- 2006 Aug;24(2):94-97.
PURPOSE: The present study investigated the effects of the type 5 phosphodiesterase(PDE-5) inhibitor, vardenafil on oxytocin expression in the paraventricular nucleus(PVN) of the hypothalamus were investigated. MATERIALS AND METHODS: Spargue-Dawley... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of Erectile Dysfunction by Penile Duplex Doppler Ultrasonography: Trimix Intracavernosal Injection Versus Vardenafil Oral Medication
-
Hwang IS, Park K
- KMID: 2226658
- Korean J Androl.
- 2005 Apr;23(1):12-16.
PURPOSE: The aims of this study were to evaluate whether vardenafil, a phosphodiesterase type 5 inhibitor, may be used as a substitute for intracavernosal injection when assessing erectile dysfunction using... -
- CITED
-
- Close
- SHARE
-
- Close
- No Causal Link between Phosphodiesterase Type 5 Inhibition and Melanoma
-
Wang JZ, Le S, Alexanian , Boddu S, Merleev A, Marusina A, Maverakis
- KMID: 2455408
- World J Mens Health.
- 2019 Sep;37(3):313-321.
- doi: 10.5534/wjmh.180050
PURPOSE: To examine the association between phosphodiesterase type 5 (PDE5) inhibitor use and melanoma by 1) conducting a systematic review of observational studies; and 2) determining if low PDE5A gene... -
- CITED
-
- Close
- SHARE
-
- Close
- Drug Interaction Study of Vardenafil 20mg and Doxazosin 4mg or Tamsulosin 0.2mg in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction to Evaluate Changes in Blood Pressure
-
Lee SY, Kim SC, Kim HW
- KMID: 2294099
- Korean J Urol.
- 2006 Sep;47(9):1001-1006.
- doi: 10.4111/kju.2006.47.9.1001
Purpose: This study aimed at evaluating the expected additive blood pressure (BP) lowering effect of vardenafil when administered in the background of chronic alpha1-blocker therapy. Materials and Methods: Patients (n=90) with... -
- CITED
-
- Close
- SHARE
-
- Close
- Examination of the Effects of Vardenafil on Esophageal Function Using Multichannel Intraluminal Impedance and Manometry
-
Lee TH, Lee JS, Hong SJ, Jeon SR, Kim WJ, Kim HG, Cho JY, Kim JO
- KMID: 2325949
- J Neurogastroenterol Motil.
- 2012 Oct;18(4):399-405.
BACKGROUND/AIMS: To evaluate the effects of the phosphodiesterase type 5 (PDE5) inhibitor vardenafil on esophageal function, including bolus transit, using multichannel intraluminal impedance and esophageal manometry (MII-EM). METHODS: Sixteen healthy volunteers... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Efficacy and Time of Onset between Vardenafil and Sildenafil in Facilitating Pelvic Nerve-Mediated Penile Erection in the Rabbit Model
-
Choi S, Rhew HY, Goldstein
- KMID: 2298667
- Korean J Androl.
- 2002 Apr;20(1):23-28.
PURPOSE: Phosphodiesterase type 5 (PDE type 5) is the predominant enzyme responsible for cGMP hydrolysis in trabecular smooth muscle. Activation of PDE type 5 terminates NO-induced, cGMP-mediated smooth muscle relaxation,... -
- CITED
-
- Close
- SHARE
-
- Close
- Abscess of the Penile Corpus Cavernosum
-
Park SM, Hwang CH, Heo C, Woo JH, Lee TH, Hong SJ, Roh SH
- KMID: 2293837
- Korean J Urol.
- 2005 Nov;46(11):1224-1227.
We present an unusual case of a penile cavernosal abscess. This patient did not improve clinically despite repeat percutaneous aspiration of the abscess and administration of oral fluoroquinolone. Surgical drainage... -
- CITED
-
- Close
- SHARE
-
- Close
- Vardenafil Enhances Oxytocin Expression in the Paraventricular Nucleus without Sexual Stimulation
-
Shin MS, Ko IG, Sung YH, Kim SE, Kim BK, Kim CJ, Lee SW, Kim DH, Chang JH, Kim KH
- KMID: 2232770
- Int Neurourol J.
- 2010 Dec;14(4):213-219.
PURPOSE: Oxytocin is associated with the ability to form normal social attachments. c-Fos is an immediate early gene whose expression is used as a marker for stimulus-induced changes in neurons.... -
- CITED
-
- Close
- SHARE
-
- Close
- New PDEs Inhibitors for Erectile Dysfunction
-
Choi HK
- KMID: 2183138
- J Korean Med Assoc.
- 2003 Nov;46(11):1050-1056.
- doi: 10.5124/jkma.2003.46.11.1050
Phosphodiesterases (PDEs) are functionally diverse enzymes with wide organ and tissue distributions. Of these enzymes, PDE5 has received particular attention largely because of the introduction and widespread use of the... -
- CITED
-
- Close
- SHARE
-
- Close
- Can the PDE5 Inhibitor Replace Intracavernosal Injection as a Method for Inducing a Penile Erection during the Evaluation of Erectile Dysfunction Using Penile Duplex Ultrasonography?
-
Ryu IW, Yoon H, Shim BS, Park YY, Chung WS
- KMID: 2311969
- Korean J Urol.
- 2008 Jul;49(7):641-646.
PURPOSE: To clarify whether vardenafil can be used as a substitute for intracavernosal injection as a method of induction of penile erection, we compared the outcome of penile duplex Doppler... -
- CITED
-
- Close
- SHARE
-
- Close
- The Comparative Effects of PDE5 Inhibitors (Zaprinast, Sildenafil and Vardenafil) according to the Route of Administration in the Rabbit Model
-
Moon I, Choi S
- KMID: 2294035
- Korean J Urol.
- 2005 Aug;46(8):849-853.
Purpose: Intracavernosal (IC) PDE5 (phosphodiesterase type 5) inhibitors, at tissue levels approaching millimolar concentrations, have been reported to cause penile erection in the absence of sexual stimulation. The objectives of... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment Strategy for Non-Responders to PDE5 Inhibitors
-
Park NC, Kim TN, Park HJ
- KMID: 2320852
- World J Mens Health.
- 2013 Apr;31(1):31-35.
Currently, phosphodiesterase type 5 (PDE5) inhibitors are the initial treatment option for erectile dysfunction. The reported efficacy of PDE5 inhibitors is about 70%, although it is significantly lower in difficult-to-treat... -
- CITED
-
- Close
- SHARE
-
- Close
- The Analysis of Preference for Three PDE-5 Inhibitors
-
Yoon CJ, Lee SH, Moon KH, Yoo ES, Park JS, Lee KS, Shin HC, Lee YW
- KMID: 2226639
- Korean J Androl.
- 2005 Dec;23(3):116-121.
PURPOSE: To evaluate the preference factors for the treatment of erectile dysfunction (ED) with three different kinds of PDE-5 inhibitors. MATERIALS AND METHODS: This prospective, open-label study recruited 140 patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Mirodenafil for the Treatment of Erectile Dysfunction: A Systematic Review of the Literature
-
Park HJ, Moon KH, Lee SW, Lee WK, Kam SC, Lee JH, Park NC
- KMID: 2320806
- World J Mens Health.
- 2014 Apr;32(1):18-27.
Phosphodiesterase type 5 (PDE5) inhibitors are the most commonly used treatment for erectile dysfunction (ED). Since the launch of sildenafil, several drugs-including mirodenafil, sildenafil citrate (sildenafil), tadalafil, vardenafil HCL (vardenafil),... -
- CITED
-
- Close
- SHARE
-
- Close
- Onset of Action of Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction
-
Son HC, Kim M, Park YH, Jeong CW, Kim HJ, Kim YJ, Huh JS
- KMID: 2226552
- Korean J Androl.
- 2008 Dec;26(4):218-222.
PURPOSE: After the market launch of multiple phosphodiesterase type 5 inhibitors (PDE5Is), a considerable amount of information has emerged regarding the efficacy and the time of initiation of these drugs.... -
- CITED
-
- Close
- SHARE
-
- Close
- Past, Present and Future of PDE5 Inhibitor
-
Kim JJ, Moon DG
- KMID: 2226569
- Korean J Androl.
- 2008 Jun;26(2):49-60.
The phosphodiesterase type-5 inhibitors (PDE5-Is) sildenafil, vardenafil and tadalafil are widely used as first-line therapy for erectile dysfunction (ED). Since the approval of sildenafil in 1998, more than 40 million... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of a 3-Dimension HMD (Head Mounted Displayer) for Audiovisual Sexual Stimulation after Oral Phosphodiesterase Type 5 (PDE 5) Inhibitor Medication for the Diagnosis of Vasculogenic Erectile Dysfunction
-
Baek UG, Moon KH
- KMID: 2293809
- Korean J Urol.
- 2005 Dec;46(12):1302-1307.
PURPOSE: The AVSS with 3-D HMD is considered to provide a more realistic image and more comfortable circumstances in which the subjects are absorbed in the stimulation. We investigated the... -
- CITED
-
- Close
- SHARE
-
- Close
- Light-controlled relaxation of the rat penile corpus cavernosum using NOBL-1, a novel nitric oxide releaser
-
Hotta Y, Ieda N, Fukamoto A, Kataoka T, Kawade Y, Maeda Y, Nakagawa H, Kimura K
- KMID: 2426497
- Investig Clin Urol.
- 2016 May;57(3):215-220.
- doi: 10.4111/icu.2016.57.3.215
PURPOSE: To investigate whether relaxation of the rat penile corpus cavernosum could be controlled with NOBL-1, a novel, light-controllable nitric oxide (NO) releaser. MATERIALS AND METHODS: Fifteen-week-old male Wistar-ST rats were... -
- CITED
-
- Close
- SHARE
-
- Close
- Analysis of Prescriptions of Alpha-Blockers and Phosphodiesterase 5 Inhibitors from the Urology Department and Other Departments
-
Kang DH, Lee JY, Chung JH, Cho HJ, Cho JM, Moon HS, Kim YT, Yoo TK, Choi HY, Park HY, Lee SW
- KMID: 2232823
- Int Neurourol J.
- 2011 Dec;15(4):216-221.
PURPOSE: We analyzed the prescriptions of alpha-blockers and phosphodiesterase 5 inhibitors (PDE5Is) in the urology department as well as in other departments of the general hospital. METHODS: We investigated the frequency... -
- CITED
-
- Close
- SHARE
-
- Close
